Five Scientific Communications at the European Academy of Allergy and Clinical Immunology Congress Further Support DBV's EPIT(TM) Disease Modifying Effect
June 10, 2014 12:05 ET
|
DBV Technologies
BAGNEUX, France, June 10, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, presented today...
DBV Announces the First reported case of a long term sustained effect of Peanut desensitization after Epicutaneous Immunotherapy (EPIT) with Viaskin(R) at the French Congress of Allergy
April 16, 2014 01:37 ET
|
DBV Technologies
Dr. Thierry Bourrier and Pr. Christophe Dupont present abstract showing that a peanut-allergic child from the ARACHILD study had a sustained desensitization even after one year off treatment...
DBV Technologies : DBV Technologies Announces Topline Financial Results for First Three Months 2014
April 15, 2014 01:33 ET
|
DBV Technologies
BAGNEUX, France, April 15, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new reference in the treatment of allergy, announced today its...
Presentation and Publication of Research at AAAAI Demonstrates EPIT(TM)'s Ability to rebalance the Immune System and Induce a Disease-Modifying Effect
March 04, 2014 12:05 ET
|
DBV Technologies
BAGNEUX, France, March 4, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, today announced that...
NIH-sponsored Consortium of Food Allergy Research (CoFAR) starts a Phase II clinical study with DBV Technologies' Viaskin(R) Peanut in the treatment of peanut allergy
October 24, 2013 02:14 ET
|
DBV Technologies
Leading US centers in food allergy will be involved in an NIH-funded CoFAR study, coordinated by Dr. Sampson and Dr. Jones in collaboration with DBV' team
CoFAR6 study will help to better...
DBV Technologies Forms Research Collaboration with Inserm to Develop Viaskin(R) for Refractory Hemophilia A Disease
October 22, 2013 12:33 ET
|
DBV Technologies
BAGNEUX, France, Oct. 22, 2013 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext:DBV) (ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies, announced today that it...
DBV Announces Topline Financial Results for First Nine Months 2013 and Provides Safety Update on Viaskin(R) Peanut
October 15, 2013 02:49 ET
|
DBV Technologies
BAGNEUX, France, Oct. 15, 2013 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext:DBV) (ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today its...